ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results. Management will also provide a brief update on the business.

CONFERENCE CALL INFORMATION
To access the live call by phone, dial (877) 621-5803; the conference ID is 5566069. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005022/en/

INVESTOR RELATIONS AND MEDIA
ImmunoGen
Courtney O'Konek
781-895-0600
[email protected]

OR

FTI Consulting
Robert Stanislaro
212-850-5657
[email protected]

Source: ImmunoGen Inc.

You May Also Be Interested In

• KBRA Upgrades State of New Jersey General Obligation Bonds to AA- and Appropriation Bonds to A+; Assigns A+ Rating to New Jersey Transportation Trust Fund Authority Transportation Program Bonds, 2026
• Fundamental Investment Management Chooses SS&C for Launch of Australian Small-Cap Fund
• Yorkton Equity Group Inc. Announces Amendment to Terms of Share Purchase Agreement Previously Announced on July 2, 2026